We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Broad Approach Required for Histoplasmosis Diagnosis

By LabMedica International staff writers
Posted on 06 Sep 2011
An immunoassay has been used to improve the diagnosis of histoplasmosis, which is often diagnosed by a combining antigen and antibody testing, as well as culture and pathology.

The sensitivity of the MVista Histoplasma antigen enzyme immunoassay (EIA) has been evaluated in disseminated histoplasmosis in patients with Acquired Immunodeficiency Syndrome (AIDS) and in the “epidemic” form of acute pneumonia.

Scientist at Indiana University (Indianapolis, IN, USA) collected serum and urine samples from 218 patients with histoplasmosis; 158 with disseminated disease and 60 with pulmonary infection, and 229 controls. The patients evaluated came from eight medical centers during the period from November 2004 through December 2007, and they were tested for Histoplasma and/or Blastomyces antigen at a commercial laboratory. The MVista Histoplasma antigen EIA was modified to permit quantification below the level of 0.6 ng/mL by incorporating 0.2 ng/mL and 0.4 ng/mL calibrators and removing those of ≥19 ng/mL. Serum specimens were treated with 4% EDTA at 104 °C before testing.

In the group with disseminated histoplasmosis, the rate of antigenuria, the presence of the specific antigen in the urine, was 91.8%. Sensitivity for the presence of the specific antigen in the serum, antigenemia, was similar. Culture findings were positive in 74.2% of cases, and similar rates were seen with pathology (76.3%) and antibody testing (75.0%). The sensitivity of the test in pulmonary cases varied, as antigenuria was positive in 83.3% of acute cases, in 87.5% of chronic cases, but in only 30.4% of subacute cases. Conversely, antibody results were positive in 66.7%, 95.1%, and 83.3% of those three categories, respectively. The control group included 30 subjects with blastomycosis, and the histoplasmosis tests were 90% cross-reactive in this group. However, the histoplasmosis antigen-enzyme immunoassay was 99% specific when tested in healthy subjects and those with nonfungal infections.

MVista Histoplasma antigen quantative sandwich EIA is a product of MiraVista Diagnostics (Indianapolis, IN, USA) where the laboratory analysis was carried out. Chadi A. Hage, MD, the senior author of the study, and his colleagues concluded that their study supports a broad approach, using antigen testing of urine and serum samples, antibody testing, culture, and pathology for diagnosis of disseminated or pulmonary histoplasmosis. The study was published online on August 2, 2011, in the journal Clinical Infectious Diseases.

Related Links:

Indiana University
MiraVista Diagnostics




Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.